BACKGROUND: Influenza is a major cause of morbidity and mortality in Canada, with up to 7000 influenza-related deaths occurring every year. The elderly and individuals with chronic diseases are at increased risk for influenza-related morbidity and mortality. METHODS: We conducted a 2-year, community cluster-randomized trial targeting elderly people and at-risk groups to assess the effectiveness of pharmacy-based influenza vaccination clinics on influenza vaccination rates. Small rural communities in interior and northern British Columbia were randomly allocated to the intervention or control. In the intervention communities, pharmacy-based influenza vaccination clinics were held and were promoted to eligible patients using personalized invitations from the pharmacists, invitations distributed opportunistically by a pharmacist to eligible patients presenting to pharmacies during the flu season and community-wide promotion using posters and the local media. The main outcome measure was a difference in the mean influenza vaccination rates. The immunization rates were calculated using the number of immunizations given in each community divided by the population size estimated from the census data. RESULTS:Baseline influenza immunization rates in the population ≥65 years of age were the same in the control (n = 10, mean 85.6% [SD 16.6]) and intervention (n = 14, mean 83.8% [SD 16.3]) communities in 2009 (p = 0.79). In 2010, the mean influenza immunization rate was 56.9% (SD 28.0) in the control communities (n = 15) and 80.1% (SD 18.4) in the intervention communities (n = 14) (p = 0.01) for those ≥65 years of age. However, in 2010, for those 2 to 64 years with chronic medical conditions, the immunization rates were lower in the intervention communities (mean 16.3% [SD 7.1]) compared with the control communities (mean 21.2% [SD 5.8]) (p = 0.04). CONCLUSION: Clinics were feasible and well attended and they resulted in increased vaccination rates for elderly residents. In contrast, vaccination rates in the younger population with comorbidities remained low and unchanged.
RCT Entities:
BACKGROUND: Influenza is a major cause of morbidity and mortality in Canada, with up to 7000 influenza-related deaths occurring every year. The elderly and individuals with chronic diseases are at increased risk for influenza-related morbidity and mortality. METHODS: We conducted a 2-year, community cluster-randomized trial targeting elderly people and at-risk groups to assess the effectiveness of pharmacy-based influenza vaccination clinics on influenza vaccination rates. Small rural communities in interior and northern British Columbia were randomly allocated to the intervention or control. In the intervention communities, pharmacy-based influenza vaccination clinics were held and were promoted to eligible patients using personalized invitations from the pharmacists, invitations distributed opportunistically by a pharmacist to eligible patients presenting to pharmacies during the flu season and community-wide promotion using posters and the local media. The main outcome measure was a difference in the mean influenza vaccination rates. The immunization rates were calculated using the number of immunizations given in each community divided by the population size estimated from the census data. RESULTS: Baseline influenza immunization rates in the population ≥65 years of age were the same in the control (n = 10, mean 85.6% [SD 16.6]) and intervention (n = 14, mean 83.8% [SD 16.3]) communities in 2009 (p = 0.79). In 2010, the mean influenza immunization rate was 56.9% (SD 28.0) in the control communities (n = 15) and 80.1% (SD 18.4) in the intervention communities (n = 14) (p = 0.01) for those ≥65 years of age. However, in 2010, for those 2 to 64 years with chronic medical conditions, the immunization rates were lower in the intervention communities (mean 16.3% [SD 7.1]) compared with the control communities (mean 21.2% [SD 5.8]) (p = 0.04). CONCLUSION: Clinics were feasible and well attended and they resulted in increased vaccination rates for elderly residents. In contrast, vaccination rates in the younger population with comorbidities remained low and unchanged.
Authors: Serigne M Ndiaye; David P Hopkins; Abigail M Shefer; Alan R Hinman; Peter A Briss; Lance Rodewald; Bayo Willis Journal: Am J Prev Med Date: 2005-06 Impact factor: 5.043
Authors: Janice K Louie; Meileen Acosta; Kathleen Winter; Cynthia Jean; Shilpa Gavali; Robert Schechter; Duc Vugia; Kathleen Harriman; Bela Matyas; Carol A Glaser; Michael C Samuel; Jon Rosenberg; John Talarico; Douglas Hatch Journal: JAMA Date: 2009-11-04 Impact factor: 56.272
Authors: Seema Jain; Laurie Kamimoto; Anna M Bramley; Ann M Schmitz; Stephen R Benoit; Janice Louie; David E Sugerman; Jean K Druckenmiller; Kathleen A Ritger; Rashmi Chugh; Supriya Jasuja; Meredith Deutscher; Sanny Chen; John D Walker; Jeffrey S Duchin; Susan Lett; Susan Soliva; Eden V Wells; David Swerdlow; Timothy M Uyeki; Anthony E Fiore; Sonja J Olsen; Alicia M Fry; Carolyn B Bridges; Lyn Finelli Journal: N Engl J Med Date: 2009-10-08 Impact factor: 91.245
Authors: Richard Kent Zimmerman; Mary Patricia Nowalk; Inis J Bardella; Michael J Fine; Janine E Janosky; Tammy A Santibanez; Stephen A Wilson; Mahlon Raymund Journal: Am J Prev Med Date: 2004-01 Impact factor: 5.043
Authors: Richard K Zimmerman; Mary Patricia Nowalk; Mahlon Raymund; Melissa Tabbarah; David G Hall; J Todd Wahrenberger; Stephen A Wilson; Edmund M Ricci Journal: Am J Public Health Date: 2003-10 Impact factor: 9.308
Authors: D MacDougall; B A Halperin; J Isenor; D MacKinnon-Cameron; L Li; S A McNeil; J M Langley; S A Halperin Journal: Hum Vaccin Immunother Date: 2016-03-03 Impact factor: 3.452
Authors: Jennifer E Isenor; Tania A Alia; Jessica L Killen; Beverly A Billard; Beth A Halperin; Kathryn L Slayter; Shelly A McNeil; Donna MacDougall; Susan K Bowles Journal: Hum Vaccin Immunother Date: 2016-02-10 Impact factor: 3.452
Authors: Sarah A Buchan; Laura C Rosella; Michael Finkelstein; David Juurlink; Jennifer Isenor; Fawziah Marra; Anik Patel; Margaret L Russell; Susan Quach; Nancy Waite; Jeffrey C Kwong Journal: CMAJ Date: 2016-08-08 Impact factor: 8.262
Authors: Jennifer E Isenor; Melissa S Kervin; Donna M Halperin; Joanne Langley; Julie A Bettinger; Karina A Top; Fawziah Lalji; Kathryn Slayter; Janusz Kaczorowski; Susan K Bowles; Nancy M Waite; Scott A Halperin Journal: Can Pharm J (Ott) Date: 2020-02-17
Authors: Benjamin S Teeter; Cynthia Mosley; Jeremy L Thomas; Bradley Martin; Duane Jones; Jose R Romero; Geoffrey M Curran Journal: Res Social Adm Pharm Date: 2019-05-29
Authors: Jennifer E Isenor; Jessica L Killen; Beverly A Billard; Shelly A McNeil; Donna MacDougall; Beth A Halperin; Kathryn L Slayter; Susan K Bowles Journal: J Pharm Policy Pract Date: 2016-10-19